

PRESS RELEASE

January 4, 2010

Dynacell Life Sciences, LLC Reports Positive 2010 a Year of Key Collaborations and Defines New Mission

Forging a Leadership Role in the Development of Novel Cell Culture Reagents

Spring House, PA. - Dynacell Life Sciences, LLC today announced that it has signed an agreement to help develop a novel cell culture matrix.

“2009 was a very exciting year for Dynacell Life Sciences,” said Ramon Garcia, Ph.D., Dynacell’s managing member. “We began several strategic collaborations as part of our continued expansion. We have built on the base of mammalian cell culture because it may prove to be the path to further major medical advances in the fight against chronic and degenerative diseases. The promising developments in adult stem cells and cell culture are building a sturdy foundation for Dynacell’s future growth.”

Becoming a global leader in cell biology

To continue its healthy expansion, Dynacell announced a new direction in its strategic mission. The Company plans to expand its technology and leadership position and increase its customer base in its core business as well as in its new businesses.

“Historically, the Company’s revenues have been derived from its core business, i.e., the sale of unique and rare cell types, bench top cell counters, and reagents to the research market,” explained Dr. Garcia. “However, Dynacell Life Sciences anticipates that new products derived from its strategic collaborations will play an important role for

those who are developing the next generation of drugs by studying the function of stem and progenitor cells and their role in disease and healing.”

Dynacell Life Sciences recently expanded its development program to serve biotechnology and pharmaceutical companies working in the fields of tumor biology as well as orphan diseases.

Anticipating a robust expansion of worldwide markets

The cell biology based markets served by Dynacell are projected to reach several billion dollars in sales over the next decade. These markets include not only the traditional culture based researchers, but include those working with siRNA molecules and ribozymes, and drugs devised from these molecules that regulate gene function.

To meet these widening demands, Dynacell is putting together a portfolio of technologies to partner with biotechnology and pharmaceutical companies and optimize their development. According to Dr. Garcia: “The Company has invested heavily in the adult stem cell market and will continue to do so.”

Dynacell also announced plans to expand its sales and marketing team as well as its current laboratory facilities. “Underlying the growth strategies is Dynacell’s commitment to customer satisfaction for delivery and service, sustained growth, product quality, and innovation,” said Dr. Garcia.

* * *

Forward-Looking Statement

The statements in this press release regarding projected results are preliminary and “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, this press release contains other forward-looking statements regarding Dynacell’s or third parties’ expectations, predictions, views, opportunities, plans, beliefs and statements of similar effect. The forward-looking statements in this press release are subject to a variety of risks and uncertainties. Actual results could differ materially.

#